• PAD4-IN-2 TFA: Targeted PAD4 Inhibition for Tumor Immunology

  2026-06-11

  PAD4-IN-2 TFA leverages meta-phenylboronic acid modification for highly selective PAD4 inhibition, allowing researchers to dissect tumor microenvironment modulation and NET formation with minimal off-target toxicity. This article translates recent mechanistic advances into actionable workflows and troubleshooting strategies for robust cancer immunology research.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-10

  Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor from APExBIO, empowers reproducible inhibition of angiogenesis and tumor cell proliferation in advanced cancer research. This guide translates key mechanistic advances and case-based findings into robust assay workflows, optimization strategies, and troubleshooting insights that outperform legacy TKIs.

• Radicicol as an Hsp90 Inhibitor: Optimizing Adipogenesis and

  2026-06-10

  Radicicol unlocks precise Hsp90 inhibition for dissecting adipogenesis, apoptosis, and inflammation pathways in advanced research models. With robust workflows and troubleshooting strategies, it empowers users to achieve reproducible results in cell signaling and disease modeling.

• Epacadostat (INCB024360) in Immune Modulation Assays

  2026-06-09

  Epacadostat (INCB024360) unlocks precise, reproducible workflows for dissecting IDO1-mediated immune evasion in translational immuno-oncology. This guide translates cutting-edge protocols and troubleshooting strategies into actionable steps, empowering researchers to leverage metabolic modulation in standard and advanced immune response assays.

• Norovirus Exploits NINJ1 for Selective NS1 Protein Secretion

  2026-06-09

  This study uncovers how murine norovirus hijacks the cell death effector NINJ1 to specifically secrete its NS1 protein, a process critical for immune evasion in the intestine. By mapping this unconventional secretion pathway, the research provides new insight into regulated plasma membrane rupture and viral-host interactions.

• Targeting CLK2 to Overcome Platinum Resistance in Ovarian Ca

  2026-06-08

  This article examines a recent study identifying Cdc2-like kinase 2 (CLK2) as a key driver of platinum resistance in ovarian cancer through enhanced DNA repair. The findings suggest therapeutic targeting of CLK2 may improve outcomes in resistant disease and inform alternative splicing modulation strategies.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-06-08

  The referenced study uncovers how ALDOB K87 lactylation orchestrates mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). These findings reveal a novel metabolic-structural axis underpinning pathological vascular remodeling, suggesting new molecular targets for intervention.

• PAD4-IN-2 TFA: Mechanistic Insights and Strategic Assay Opti

  2026-06-07

  Explore how PAD4-IN-2 TFA uniquely enables selective PAD4 inhibition in tumor cells, offering advanced modulation of the tumor immune microenvironment. This article provides deep mechanistic analysis and practical guidance for optimizing cancer research assays using Compound 5i TFA.

• Troglitazone as a PPARγ Agonist: Protocols for SPP1 and TAM

  2026-06-06

  Troglitazone stands out as a dual PPARγ/α agonist, uniquely enabling translational workflows that bridge metabolic studies and immuno-oncology. This article delivers actionable protocol enhancements and troubleshooting tips for researchers targeting lipid/glucose metabolism or SPP1-driven tumor microenvironments.

• Sulfo-Cy5 Carboxylic Acid: Precision Fluorescent Dye for Lif

  2026-06-05

  Sulfo-Cy5 carboxylic acid is a highly water-soluble, sulfonated fluorescent dye for life sciences, offering robust fluorescence and minimized quenching for protein and peptide labeling. Its defined excitation/emission properties (646/662 nm) and compatibility with aqueous workflows make it a standard for high-sensitivity imaging and detection. This article details molecular properties, benchmarks, and critical workflow considerations, providing evidence-based guidance for advanced research.

• RapaLink-1: Advancing mTORC1 Inhibition in Translational Res

  2026-06-05

  Explore how RapaLink-1, a third-generation mTOR inhibitor from APExBIO, delivers unprecedented control over the PIK3CA–AKT–mTOR pathway for both cancer and developmental studies. This article integrates mechanistic depth, protocol insights, and strategic guidance to empower translational researchers seeking robust, reproducible results in glioma, embryonic dormancy, and beyond.

• Troglitazone (A3893): Reliable PPARγ Agonist for Translation

  2026-06-04

  This article delivers scenario-driven guidance for deploying Troglitazone (SKU A3893) as a selective PPARγ/α agonist in cell viability, proliferation, and tumor microenvironment studies. Emphasizing data integrity and protocol optimization, it cross-references peer-reviewed evidence and real-world workflow challenges addressed by APExBIO's high-purity Troglitazone.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-06-04

  This study demonstrates that PPARγ activation regulates macrophage polarization via STAT-1/STAT-6 signaling to attenuate experimental inflammatory bowel disease (IBD). The findings provide mechanistic insight into how PPARγ agonists, including pioglitazone, modulate immune responses and support targeted preclinical workflows for inflammatory disease research.

• Carvacrol in Redox and Cell Cycle Research: Applied Protocol

  2026-06-03

  Carvacrol (5-isopropyl-2-methylphenol) stands out for its unique ability to modulate cell cycle arrest and apoptosis, while offering powerful redox modulation for TRP channel studies. This article translates cutting-edge bench research into actionable workflows, protocol enhancements, and troubleshooting insights to maximize Carvacrol's impact in experimental biology.

• 17-AAG (Tanespimycin): Optimized HSP90 Inhibition Workflows

  2026-06-03

  17-AAG (Tanespimycin) empowers cancer researchers with nanomolar HSP90 inhibition, enabling precise oncogenic protein degradation and robust apoptosis induction. This guide translates cutting-edge findings and troubleshooting strategies into actionable, reproducible workflows for advanced oncology studies.

8364 records 9/558 page Previous Next First page 上5页 678910 下5页 Last page